The Australian Government is improving the Consumer Medicine Information (CMI) given to patients after doctors and consumer health advocates raised concerns regarding the complexity and readability of
Johnson & Johnson Vision has unveiled its next-generation monofocal intraocular lens (IOL), the Tecnis Eyhance IOL. Tecnis Eyhance is the first in the monofocal IOL
An Australian study examined the experiences of adult students with Irlen Syndrome and dyslexia to help education institutions provide better support to those with both.Collaborative research was
Neutrogena Visibly Clear Light Therapy Acne Mask and Activator has been recalled due to fears it causes retinal damage.Johnson & Johnson Pacific, in consultation with Australian Department of Health’s
To cope with the growing treatment crisis, the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) has backed the right for ophthalmologists to train hospital-based optometrists to
A state-of-the-art medical imaging, research and innovation centre will be built in Tairāwhiti Gisborne with $6 million from the Government’s Provincial Growth Fund and $1 million from the Eastland
Ocuphire Pharma has announced late phase II clinical trials can begin on its eye drop Nyxol after receiving $5 million funding to further develop the drug.Phase I and phase II trials proved successful
A few extra few million dollars a year would dramatically cut the number of people needing cataract operations and save millions and millions of dollars helping people hurt by falls, a new Otago study
Blind Foundation changes The Blind Foundation has appointed Canadian John Mulka as its new chief executive, replacing long-term CEO Sandra Budd, who’s contract ended at the end of June. For the past
A first-of-its-kind continuous delivery system of an anti-VEGF therapy to treat wet age-related macular degeneration is a step closer now patient enrolment for a phase III clinical trial is complete.
The Royal Victorian Eye and Ear Hospital is seeking patients for a phase II clinical study of Okogen’s OKG-0301 to treat viral conjunctivitis.In partnership with the Centre for Eye Research Australia
